ATR/CHK1 pathway inhibitors represent a therapeutic option for platinum-resistant high-grade serous ovarian carcinoma (HGSOC). Here the authors report the results of a phase 2 clinical study of the CHK1 inhibitor prexasertib in patients with BRCA wild-type platinum-resistant HGSOC with or without biopsiable disease.
All Keywords
【저자키워드】 Translational research, Targeted therapies, Predictive markers, ovarian cancer,
【저자키워드】 Translational research, Targeted therapies, Predictive markers, ovarian cancer,